

## AUTHOR INDEX

- Advani, S.J., 633  
 Ahmed, M.M., 732  
 Anderson, K.C., 141  
 Antman, K.H., 556  
 Aplan, P.D., 45  
 Applebaum, F.R., 114  
 Arbuck, S.G., 219  
  
 Büchner, T., 124  
 Baker, L.H., 592  
 Belani, C.P., 440  
 Ben-Ari, G., 547  
 Biermann, J.S., 592  
 Bishop, J.E., 57  
 Bloomfield, C.D., 1, 17  
 Boone, C.W., 241  
 Bramwell, V.H.C., 561  
 Broderick, L.S., 411  
 Bunn, P.A.Jr., 288  
  
 Calgiuri, M.A., 32  
 Camtra, B.M., 83  
 Carbone, D.P., 388  
 Carsons, S., 360  
 Chanock, S.J., 132  
 Charles, C., 616  
 Chmura, S.J., 633  
 Chomienne, C., 92  
 Choy, H., 477  
 Christian, M.C., 219  
 Chute, J.P., 492  
 Clegg, S., 616  
 Cohen, P.R., 334  
 Colvin, O.M., 580  
 Conces, D.J.Jr., 411  
 Corn, B.W., 707  
 Cortazar, P., 492  
 Cragg, G.M., 156  
 Crowell, J.A., 241  
 Curran, W.J.Jr., 707  
  
 Dalmau, J.O., 318  
 de la Chapelle, A., 17  
 Degos, L., 92  
 Dewhirst, M.W., 616  
 Dinarello, C.A., 288  
 Eckardt, J., 526  
 Eggermont, A.M.M., 547  
 Eilber, F.R., 526  
  
 Feins, R.H., 419  
 Fenaux, P., 92  
 Fishbane, S., 373  
 Fossella, F.V., 455  
 Fraumeni, J.F.Jr., 504  
  
 Gebhardt, M.C., 540  
 Gillette, E., 616  
 Gilliland, D.G., 32  
 Glantz, M.J., 477  
 Goldstein, D.J., 534  
  
 Griffin, R.J., 626  
 Gunderson, L.L., 715  
  
 Haddock, M.G., 715  
 Hall, T.C., 265, 269  
 Harmon, D.C., 540  
 Harrison, L.B., 715  
 Hart, K.B., 745  
 Hawk, E.T., 241  
 Heinecke, A., 124  
 Heinonen, K., 17  
 Hibshoosh, H., 515  
 Hiddeman, W., 124  
 Ho, P.T., 187, 219  
 Holmlund, J., 173  
 Hong, W.K., 455  
  
 Iliakis, G., 602  
 Innig, G., 124  
  
 Jackson, R.C., 164  
 Jennings, L.C., 540  
 Johnson, B.E., 492  
 Johnson, D.H., 387, 484  
  
 Karp, D.D., 402  
 Karp, J.E., 103, 241  
 Kelloff, G.J., 241  
 Keohan, M.L., 572  
 Klausner, J.M., 547  
 Koops, H.S., 547  
 Kroon, B.B.R., 547  
 Kurzrock, R., 334  
  
 Laport, G.E., 70  
 Laramore, G.E., 672  
 Larson, R.A., 70  
 LaRue, S., 616  
 Lattes, R., 515  
 Lee, J.S., 455  
 Lejeune, F.J., 547  
 Lienard, D., 547  
 Loeffler, J.S., 686, 707  
 Lubert, R.A., 241  
 Ludwig, W.D., 124  
  
 MacFall, J., 616  
 Maesaka, J.K., 373  
 Mani, S., 253  
 Mankin, H.J., 540  
 Maschmeier, G., 124  
 Michler, R.E., 534  
 Mittal, S.K., 373  
 Mohiuddin, M., 732  
 Mrozek, K., 17  
 Murgo, A.J., 219  
 Murphy, S., 83  
  
 Nathanson, L., 265, 277  
 Newman, D.J., 156  
  
 Odell, W., 299  
 Okajima, K., 626  
  
 Park, C.H., 639  
 Parkinson, D.R., 187  
 Petersen, I.A., 715  
 Pizzo, P.A., 132  
 Pluda, J.M., 203, 219  
 Porter, A.T., 745  
 Posner, J.B., 318  
 Prescott, D., 616  
 Prosnitz, L., 616  
 Puccio, M., 277  
 Pullen, J., 83  
 Purdy, J.A., 655  
  
 Ramanathan, R.K., 440  
 Ratain, M.J., 253  
 Rosner, G., 616  
 Ross, J.A., 3  
 Rottman, R., 124  
 Ruckdeschel, J.C., 429  
  
 Samulski, T., 616  
 Sandler, A.B., 463  
 Sandler, D.P., 3  
 Sauerland, M.C., 124  
 Sausville, E.A., 219  
 Schlag, P.M., 547  
 Shakil, A., 626  
 Shrieve, D.C., 707  
 Sigman, C.C., 241  
 Smith, A.R., 686  
 Smith, M.A., 103  
 Song, C.W., 626  
 Spiro, I.J., 540  
 Staszewski, H., 329  
 Steele, V.E., 241  
 Stritt, J.A., 696  
 Strout, M.P., 32  
 Suit, H.D., 540, 686  
 Szol, M., 173  
  
 Tarver, R.D., 411  
 Taub, R.N., 503, 572  
 Thandla, S., 45  
 Thomadsen, B.R., 696  
 Thrall, D., 616  
  
 Wörmann, B., 124  
 Wagner, H.Jr., 423  
 Webb, I.J., 141  
 Weichselbaum, R.R., 633  
 Weiss, R.B., 153, 156  
 Willert, C.G., 715  
  
 Yee, L., 477  
  
 Zühlsdorf, M., 124  
 Zahm, S.H., 504

## AUTHOR INDEX

- Advani, S.J., 633  
 Ahmed, M.M., 732  
 Anderson, K.C., 141  
 Antman, K.H., 556  
 Aplan, P.D., 45  
 Applebaum, F.R., 114  
 Arbuck, S.G., 219  
  
 Büchner, T., 124  
 Baker, L.H., 592  
 Belani, C.P., 440  
 Ben-Ari, G., 547  
 Biermann, J.S., 592  
 Bishop, J.E., 57  
 Bloomfield, C.D., 1, 17  
 Boone, C.W., 241  
 Bramwell, V.H.C., 561  
 Broderick, L.S., 411  
 Bunn, P.A., Jr., 288  
  
 Calgiuri, M.A., 32  
 Camtra, B.M., 83  
 Carbone, D.P., 388  
 Carsons, S., 360  
 Chanock, S.J., 132  
 Charles, C., 616  
 Chmura, S.J., 633  
 Chomienne, C., 92  
 Choy, H., 477  
 Christian, M.C., 219  
 Chute, J.P., 492  
 Clegg, S., 616  
 Cohen, P.R., 334  
 Colvin, O.M., 580  
 Conces, D.J., Jr., 411  
 Corn, B.W., 707  
 Cortazar, P., 492  
 Cragg, G.M., 156  
 Crowell, J.A., 241  
 Curran, W.J., Jr., 707  
  
 Dalmau, J.O., 318  
 de la Chapelle, A., 17  
 Degos, L., 92  
 Dewhirst, M.W., 616  
 Dinarello, C.A., 288  
 Eckardt, J., 526  
 Eggermont, A.M.M., 547  
 Eilber, F.R., 526  
  
 Feins, R.H., 419  
 Fenaux, P., 92  
 Fishbane, S., 373  
 Fossella, F.V., 455  
 Fraumeni, J.F., Jr., 504  
  
 Gebhardt, M.C., 540  
 Gillette, E., 616  
 Gilliland, D.G., 32  
 Glantz, M.J., 477  
 Goldstein, D.J., 534  
  
 Griffin, R.J., 626  
 Gunderson, L.L., 715  
  
 Haddock, M.G., 715  
 Hall, T.C., 265, 269  
 Harmon, D.C., 540  
 Harrison, L.B., 715  
 Hart, K.B., 745  
 Hawk, E.T., 241  
 Heinecke, A., 124  
 Heinonen, K., 17  
 Hibshoosh, H., 515  
 Hiddeman, W., 124  
 Ho, P.T., 187, 219  
 Holmlund, J., 173  
 Hong, W.K., 455  
  
 Iliakis, G., 602  
 Innig, G., 124  
  
 Jackson, R.C., 164  
 Jennings, L.C., 540  
 Johnson, B.E., 492  
 Johnson, D.H., 387, 484  
  
 Karp, D.D., 402  
 Karp, J.E., 103, 241  
 Kelloff, G.J., 241  
 Keohan, M.L., 572  
 Klausner, J.M., 547  
 Koops, H.S., 547  
 Kroon, B.B.R., 547  
 Kurzrock, R., 334  
  
 Laport, G.E., 70  
 Laramore, G.E., 672  
 Larson, R.A., 70  
 LaRue, S., 616  
 Lattes, R., 515  
 Lee, J.S., 455  
 Lejeune, F.J., 547  
 Lienard, D., 547  
 Loeffler, J.S., 686, 707  
 Lubert, R.A., 241  
 Ludwig, W.D., 124  
  
 MacFall, J., 616  
 Maesaka, J.K., 373  
 Mani, S., 253  
 Mankin, H.J., 540  
 Maschmeier, G., 124  
 Michler, R.E., 534  
 Mittal, S.K., 373  
 Mohiuddin, M., 732  
 Mrozek, K., 17  
 Murgo, A.J., 219  
 Murphy, S., 83  
  
 Nathanson, L., 265, 277  
 Newman, D.J., 156  
  
 Odell, W., 299  
 Okajima, K., 626  
  
 Park, C.H., 639  
 Parkinson, D.R., 187  
 Petersen, I.A., 715  
 Pizzo, P.A., 132  
 Pluda, J.M., 203, 219  
 Porter, A.T., 745  
 Posner, J.B., 318  
 Prescott, D., 616  
 Prosnitz, L., 616  
 Puccio, M., 277  
 Pullen, J., 83  
 Purdy, J.A., 655  
  
 Ramanathan, R.K., 440  
 Ratain, M.J., 253  
 Rosner, G., 616  
 Ross, J.A., 3  
 Rottman, R., 124  
 Ruckdeschel, J.C., 429  
  
 Samulski, T., 616  
 Sandler, A.B., 463  
 Sandler, D.P., 3  
 Sauerland, M.-C., 124  
 Sausville, E.A., 219  
 Schlag, P.M., 547  
 Shakil, A., 626  
 Shrieve, D.C., 707  
 Sigman, C.C., 241  
 Smith, A.R., 686  
 Smith, M.A., 103  
 Song, C.W., 626  
 Spiro, I.J., 540  
 Staszewski, H., 329  
 Steele, V.E., 241  
 Stritt, J.A., 696  
 Strout, M.P., 32  
 Suit, H.D., 540, 686  
 Szol, M., 173  
  
 Tarver, R.D., 411  
 Taub, R.N., 503, 572  
 Thandla, S., 45  
 Thomadsen, B.R., 696  
 Thrall, D., 616  
  
 Wörmann, B., 124  
 Wagner, H.Jr., 423  
 Webb, I.J., 141  
 Weichselbaum, R.R., 633  
 Weiss, R.B., 153, 156  
 Willert, C.G., 715  
  
 Yee, L., 477  
  
 Zühlsdorf, M., 124  
 Zahm, S.H., 504

## SUBJECT INDEX

- Acanthosis nigricans, 345, 349-352  
 clinical characteristics of, 340  
 patient workup in, 341
- Acclarubicin, in acute myeloid leukemia, 60-62
- Acquired tylosis, 350  
 clinical characteristics of, 340  
 patient workup in, 341
- Acrokeratosis paraneoplastica, 350-351
- Actin, soft tissue sarcoma and, 517
- Actinomycin D, for advanced sarcoma, 575
- Acute leukemia  
 in adults, 3-16  
 allogeneic hematopoietic stem cell transplantation in, 114-123  
 benzene and, 8  
 environmental exposures and, 9  
 epidemiology of, 3-16  
 genetic abnormalities in, 7  
 genetic factors in, 7  
 hair dye and, 10  
 hypotheses in, 10-11  
 ionizing radiation and, 8  
 nonionizing radiation and, 8-9  
 pesticides and, 9  
 petrochemical industry and, 9  
 proto-oncogenes of, 7  
 rubber industry and, 9  
 smoking and, 9-10  
 therapy in, infectious complications following, 132-140  
 transfusion support in, 141-146
- Acute lymphoblastic leukemia  
 allogeneic hematopoietic stem cell transplantation in, 116-118  
 B lineage, 46-49  
 B-cell, 75-76  
 B-cell precursor, 47-49  
 Burkitt-type, 75-76  
 CNS prophylaxis in, 73-74  
 consolidation in, 72-73  
 in elderly, 78-79  
 future directions in, 80  
 intensification therapy in, 72-73  
 maintenance in, 73  
 pH chromosome-positive, 76-77  
 postremission regimens for, 71  
 prognostic factors in, 74-75  
 relapsed, 79  
 remission induction in, 70-72  
 remission induction regimens for, 71  
 T-cell, 49-52, 77  
 translocations in, 46, 50  
 treatment of, 70-82
- Acute lymphocytic leukemia  
 childhood, see Childhood acute lymphocytic leukemia  
 molecular biology of, 45-56
- Acute myeloid leukemia  
 adult, treatment of, 57-69
- Acute myeloid leukemia (*Continued*)  
 age differences in, 20-21  
 allogeneic hematopoietic stem cell transplantation in, 114-116  
 chromosome band 11q23 rearrangements in, 32-35  
 clinical outcome in, 22-28  
 complete remission duration in, 27  
 complete remission rates in, 23-27  
 complete response in, 65-66  
 core binding factor translocations in, 37-40  
 cytogenetics in, clinical significance of, 17-31  
 early intensification therapy in, 64-65  
 ETS family member translocations in, 40  
 French-American-British subtype of, 21-22  
 gender differences in, 20  
 hematopoietic growth factors in, 124-131  
 induction chemotherapy in, 59-62  
 induction therapy in, 57-59  
 intensified therapy in, 64  
 karyotype and clinical feature correlation in, 20-22  
 late intensification therapy in, 64-65  
 molecular abnormalities in, 33  
 molecular biology of, 32-44  
 morphology in, 21-22  
 nuclear pore component rearrangements in, 40  
 postremission therapy in, 62-64  
 presenting hematologic parameters in, 21  
 primary chromosome aberrations in, 19  
 prognostic factors in, karyotype as, 22-23  
 prognostic subsets in, 65  
 secondary, following alkylating agents, 103-104  
 specific chromosome findings in, clinical outcome by, 24-26  
 survival in, 27-28  
 therapy of, future directions in, 64  
 topoisomerase-associated, 105-107  
 treatment of, 57-69
- Acute promyelocytic leukemia  
 all-trans retinoic acid alone in, 95-98  
 biology of, recent advances in, 92-94  
 bone marrow transplantation in, 98  
 chemotherapy alone in, 94-95  
 coagulopathy in, 94  
 cytogenetics of, 92  
 cytological characteristics of, 92  
 immunophenotypic characteristics of, 92  
 intensive chemotherapy in, following all-trans retinoic acid, 95-96  
 leukemic cells in, retinoic acid differentiation of, 93  
 leukemogenesis in, molecular basis of, 93  
 minimal residual disease in, 98  
 molecular definition of, 92  
 refractory, treatment of, 98-99  
 relapsing, all-trans retinoic acid in, 96  
 treatment of, 94-99
- Adaptive feedback, 619
- Adenovirus, 136
- Adrenocorticotrophic hormone, 390

- Adrenocorticotropin, cancer production of, 300-302  
 Adrenocorticotropin syndrome, ectopic, 300-302  
 AG2034, 166  
 AG331, 166  
 AG3340, 166, 209  
 Age, in childhood acute lymphocytic leukemia, 83  
 AIDS, soft tissue sarcoma associated with, 508  
 Alcohol consumption, and childhood acute leukemia, 5-6  
 Aldehyde dehydrogenase, 582  
 ALL-1 gene, 48  
   partial tandem duplication of, 36  
 All-trans-N-(4-hydroxy)retinamide, 241, 243, 246, 247  
 Allogeneic hematopoietic stem cell transplantation  
   in acute lymphoblastic leukemia, 116-118  
   in acute myeloid leukemia, 114-116  
   preparative regimen for, 119-121  
 Alpha 1 antichymotrypsin, soft tissue sarcoma and, 517  
 Alpha 1-antitrypsin, soft tissue sarcoma and, 517  
 Alpha tocopherol, 405  
 Alpha Tocopherol Beta Carotene study, 404-405  
 Alveolar rhabdomyosarcoma, 522  
 Amino precursor uptake and deamination cell, 299-300  
 9-Aminocaprothecin, 157, 162  
 AML 1-ETO fusion protein, 37, 38  
 AML1-EV11 fusion, 38  
 Amputation, in soft tissue sarcoma, 529  
 Amsacrine  
   for acute promyelocytic leukemia, 94-95  
   for adult acute myeloid leukemia, 59-62  
 Amyloidosis, 335, 344  
   amyloid light chain-related, 379  
   clinical characteristics of, 338  
   patient workup in, 339  
 Anaphase promoting complex, 605, 606  
 Anemia, 329-330  
 Angiogenesis, 392  
 Angiogenesis-dependent tumor growth, 203-204  
   antitumor development strategies and, 211-212  
   clinical outcome and, 204-205  
   initiation of, 205-206  
   pathogenesis of, 206  
   regulators of, 207-209  
   therapeutic agents in, 209-211  
 Angiogenic polypeptide, endogenous, 204  
 Angioimmunoblastic lymphadenopathy with dysproteinuria,  
   368  
 Angiostatin, 209  
 Anlagen  
   foregut, 270-271  
   hematopoietic, 272-273  
   hindgut, 271  
   immunological, 272-273  
   mesenchymal, 272-273  
   neural, 273  
   urogenital, 271-272  
 Anorexia  
   in cancer, 279-280  
   mechanisms of, 278  
 Anorexia cachexia syndrome, 278-279  
 Antennapedia gene, 34  
 Anthracyclines, for soft tissue sarcomas, 584-586  
 Anti-HU, testing for, 325  
 Anti-RL, testing for, 325  
 Anti-synthetase, 364  
 Anti-YO, testing for, 325  
 Antibody(ies)  
   antineuronal, 321, 325  
   antineutrophil cytoplasmic, 366  
   auto-, 320-321  
 Antibody-dependent cellular cytotoxicity, 177  
 Antidiuretic hormone, cancer-produced, 307-308  
 Antineuronal antibody, testing for, 321, 325  
 Antineutrophil cytoplasmic antibodies, 366  
 Antipyretic  
   mechanism of, 295  
   non-steroidal anti-inflammatory drug as, 296-297  
 Antisense oligonucleotide  
   analogues of, 190  
   in cancer therapy, 187-202  
   cellular uptake of, 190  
   gene inhibition by, 189  
   history of, 188  
   length of, 189  
   manufacture cost of, 191  
   mechanism of action of, 188  
   phosphorothioate, 191  
   preclinical evaluation of, 190-191  
   protein interactions and, 191  
   stability of, 188-189  
   target sequence selection and, 190  
 Antitumor agent(s)  
   antigen-specific, 173-186  
   from marine sources, 158  
   from microbial sources, 158-159  
   from nature, 156-163  
   from plant sources, 156-158  
   new, 153-155  
   newly marketed, 157  
   supply of, 160-162  
 Anthracenediones, for soft tissue sarcomas, 584-586  
 Apoptosis, 244  
   ontogeny and, 269  
 AR177, 194  
 Area under the curve, 253  
 Arginine vasopressin, 391  
   cancer-produced, 307-308  
 Arthritis, rheumatoid, 360-362  
 Arthritis syndrome, 340, 354  
 Asparaginase  
   in adult acute lymphoblastic leukemia, 71  
   methotrexate, vincristine, dexamethasone regimen, in adult  
   acute lymphoblastic leukemia, 74  
 Aspirin, 247  
 Astrocytoma, proton beam therapy in, 692  
 Ataxia telangiectasia  
   acute leukemia and, 4  
   DNA damage repair and, 107-109  
 ATRA syndrome, 95-98  
 Australian Leukemia Study Group, 58  
 Autoantibodies, in paraneoplastic syndromes, 320-321  
 Autocrine growth loop, 391  
 Avian erythroblastosis virus transforming sequence, 519

- Baccatin, 157
- Bacterial infection, following acute leukemia therapy, 133-134
- Basal layer, vacuolar alteration of, 355-356
- Batimastat, 209-210
- Bazex' syndrome, 350-351
- clinical characteristics of, 340
  - patient workup in, 341
- bcl-2, 194-195
- Benzene, 6
- and adult acute leukemia, 8
- Benzo(a)pyrene, 392
- Benzophenylurea, 231
- Benzyl isothiocyanate, 405
- Beta Carotene and Retinol Efficacy Trial study, 404-405
- Beta core, of human chorionic gonadotropin, 307
- Beta-carotene, 247, 249
- Berulic acid, 162
- Bimolane, 106
- Biological equivalent dose, increasing, in conformal external beam radiotherapy, 749-751
- Biopsy, needle v excision, in soft tissue sarcoma, 595
- Birth weight, high, and childhood acute leukemia, 5
- Bisantrene, 157
- Bithorax gene, 34
- Bizelesin, 162, 229-230
- molecular structure of, 230
- Bladder cancer
- intraoperative irradiation, 723
  - intraoperative radiation therapy for, 725
- Blast cell kill, 66
- Blood transfusion (s)
- alterations to, 144
  - indications for, 141-142
  - infectious risks of, 142
  - noninfectious risks of, 142-144
- Bloom syndrome
- acute leukemia and, 4
  - DNA damage repair and, 107-109
- Blush, tumor, 273
- Body mass, lean, 277-278
- Bone marrow stem cell support, in SCLC, 468
- Bone marrow transplantation, in acute promyelocytic leukemia, 98
- Bone pain, radionuclide palliation of, 641-643
- Boron neutron capture therapy, 672-676
- Brachytherapy
- dose-volume histograms in, 703-704
  - geometric optimization in, 702
  - high-dose-rate, 696-698
  - human factors in, 698-699
  - image-based, 701
  - inhomogeneity correction in, 701-702
  - intraoperative, 715-717
  - intravascular, 699-700
  - iterative optimization in, 702-703
  - new isotopes for, 704
  - optimization of, 702-703
  - in prostate cancer, 747, 748
  - pulse-dose-rate, 696, 698
  - specified dose point optimization in, 702
- Brachytherapy (*Continued*)
- technologic innovations in, 700-701
  - treatment planning with, 701
- Bragg peak, 686, 687
- spread-out, 686, 687
- Brain metastasis
- alternative therapies for, 480
  - of SCLC, 477-478
- Bronchioloalveolar carcinoma, 389
- Bryostatins-1, 158, 162, 220-221
- molecular structure of, 222
  - supply of, 161
- Butadiene, 9
- Buthionine sulfoximine, 581
- Bystander effect, 274
- c-erb-B1, 391-392
- c-myc amplification, 395
- c-myb, 196-197
- C2B8, 177
- Cachexia syndrome
- cancer and, 277-287
  - clinical manifestations of, 279-280
  - clinical significance of, 279
  - corticosteroids in, 282
  - cyproheptadine in, 284
  - delta-9-tetrahydrocannabinol in, 284
  - dronabinol in, 284
  - gastrointestinal complications of, 280
  - hydrazine sulfate in, 284
  - mediators in, 278-279
  - medroxyprogesterone acetate in, 282
  - megestrol acetate in, 282
  - melatonin in, 285
  - metabolic pathophysiology of, 277-278
  - metoclopramide in, 283
  - nutritional management of, 280-281
  - nutritional support in, 281
  - overview of, 285
  - pentoxifylline in, 284
  - pharmacologic treatment of, 282-285
  - quality of life effects of, 280
  - randomized therapy trials in, 283
- Calcium, 247, 249
- CAN gene, 40
- Cancer
- ACTH production by, 300-302
  - arginine vasopressin production by, 307-308
  - cachexia syndrome of, 277-287
  - carotenoid intake and, 404-405
  - dermatologic manifestations of, 335
  - effects of, on musculoskeletal system, 369
  - endocrine syndromes of, 299-317
  - erythropoietin production by, 308-309
  - growth hormone produced by, 308
  - growth hormone releasing hormone produced by, 308
  - hormone precursors of, 299-300
  - hypercalcemia and, 302-304
  - hypoglycemia and, 304-306
  - hypophosphatemia and, 309-310
  - increased risk for, 403
  - metabolic syndromes of, 299-317

- Cancer (Continued)  
  molecular epidemiology in, 403  
  pre, lesion therapy in, 248  
  prolactin produced by, 310-311  
  protein hormones of, 299-300  
  renin produced by, 311  
  retinoid intake and, 404  
  vitamin A intake and, 404  
Cancer family, 403  
Cancer Therapy Evaluation Program, new agents in, 219-240  
Cancer vaccine  
  defined antigen, 174  
  investigational new drug, 175  
  for serologic responses, 174  
  for T lymphocyte immune responses, 174-177  
  from tumor cells, 173-174  
Carbogen breathing, effects of, 627  
Carboplatin, for advanced sarcoma, 575  
Carboplatin-paclitaxel combination therapy  
  for NSCLC, 444-445  
  phase II trial of, 445  
  randomized trials of, 446  
Carboxyamido-triazole, 222-223  
  molecular structure of, 224  
Carcinogen, inhibition of, 246-247  
Carcinogenesis  
  genetic risk of, interventions for, 247-248  
  multistep, 403  
Carcinoma in situ, 402-410  
  management of, 407-408  
Cardiac transplantation  
  orthotopic, 534-539  
  worldwide experience with, for cardiac tumors, 538  
Cardiac tumor  
  mesna, doxorubicin, ifosfamide, dacarbazine regimen for, 537  
  orthotopic cardiac transplantation for, 534-539  
Carmustine, 582-583  
  in acute lymphoblastic leukemia, 70-72  
Carotenoid, in diet, 404-405  
Catechins, 6  
Catheter, intra-, high dose radiation via, 704  
CBF beta-MYH 11 fusion protein, 39  
CD31, 518  
CD34, 518  
Cell cycle  
  events leading to, 606  
  growth signaling and, 606-607  
  transition regulation in, 604-605  
Cell cycle regulation  
  cell cycle transitions in, 602-603  
  cell progression in, 603-604  
  chromosome cycle in, 602-603  
  chromosome states in, 603-604  
  early developments in, 602  
  in irradiated cells, 607-612  
  in nonirradiated cells, 602-607  
Central nervous system prophylaxis  
  in acute lymphoblastic leukemia, 73-74  
  in childhood acute lymphocytic leukemia, 87  
Cervical spine sarcoma, proton beam therapy in, 692  
CGP64128A, 193  
CGP69846A, 193  
Charged-particle irradiation, 707  
Checkpoint, concept of, 607  
Chemical exposure, and childhood acute leukemia, 6  
Chemicals, occupational, soft tissue sarcoma and, 506-507  
Chemoprevention  
  agents for, development of, 246-249  
  cell fate and, 244  
  clinical, characteristics of, 243  
  clinical trials in, 406-407  
  development of, prospects for, 249-250  
  empirical targets for, 241-243  
  intermediate endpoints in, 406  
  lung cancer and, 402-410  
  mechanisms for, 242  
  molecular targets for, 241  
  progress in, 241-252  
  specific agents for, 403-404  
  strategies for, 241-246  
Chemopreventive agent(s)  
  class study approach to, 243  
  development of, steps in, 243-246  
  potential activities of, 243  
Chemopreventive therapy, 407-408  
Chemoradiation  
  in rectal cancer, 735, 736  
  protocol for, 736  
Chemoradiotherapy  
  in SCLC, 470, 472-473  
  phase II trials of, 432  
  timing of, 473  
Chemotherapy  
  combination, in SCLC, 471  
  current, in NSCLC, 441  
  dose intensification of, for osteosarcoma, 569  
  early v late intensification of, 64-65  
  for advanced NSCLC, 440-454  
  history of, in NSCLC, 440-441  
  induction, in adult acute myeloid leukemia, 59-62  
  intensification of, 64  
  isolated limb perfusion and, with tumor necrosis factor alpha, 547-555  
  patient response to, 573  
  postremission, in adult acute myeloid leukemia, 62-64  
  postremission regimens of, for adult acute lymphoblastic leukemia, 71  
  preoperative, phase II trials of, 432  
  in prostate cancer, 751-752  
  remission induction regimens of, 71  
  in SCLC, 463  
  single-agent, in NSCLC, 441  
  toxicity of, prediction of, 488  
Chick chorioallantoic membrane assay, 209  
Chicken pox, soft tissue sarcoma associated with, 508  
Childhood acute leukemia  
  alcohol consumption and, 5-6  
  chemical exposure and, 6  
  cigarette smoking and, 5-6  
  epidemiology of, 3-16  
  familial patterns in, 5  
  fetal loss history and, 5

- Childhood acute leukemia (*Continued*)  
 genetic abnormalities in, 5  
 genetic syndromes of, 4  
 high birth weight in, 5  
 international patterns in, 4  
 ionizing radiation and, 5  
 two- to five-year age peak of, 6  
 United States incidence of, 4
- Childhood acute lymphocytic leukemia  
 age in, 83  
 biology of, 83-86  
 bone marrow transplantation in, 88  
 CNS protection in, 87  
 CNS relapse in, 88  
 common translocations in, 85  
 cytogenetics in, 84-86  
 Down syndrome and, 87  
 drug-sensitivity testing in, 86  
 early response in, 87  
 event-free survival in, 85  
 immunophenotype in, 83-84  
 late sequelae in, 88  
 marrow relapse in, 88  
 pharmacology in, 86  
 results in, 86-87  
 testicular relapse in, 88  
 treatment duration in, 88  
 treatment of, 86-88, 86-91  
 white blood cell count in, 83
- Chk-1, 108
- Chlorophenols, soft tissue sarcoma associated with, 506-507
- Chondrosarcoma, extraskeletal myxoid, 521
- CHOP gene, 521-522
- Chromosomal translocation, soft tissue sarcoma and, 519
- Chromosome(s)  
 primary abnormalities of, 18  
 secondary abnormalities of, 18-20
- Chromosome 11, 106, 7
- Chromosome 11q23, acute myeloid leukemia associated with, 105-107
- Chromosome 16, 7  
 pericentric inversion of, 39
- Chromosome 21, 37
- Chromosome 5, 106  
 deletions of, 7  
 in secondary leukemias, 104
- Chromosome 7, deletions of, 7
- Chromosome 8, 37
- Chromosome 9, 7
- Chromosome band 11q23  
 abnormalities of, 7  
 in normal cytogenetic patients, 37  
 rearrangements of, in acute myeloid leukemia, 32-37
- Chromosome cycle  
 cell cycle transitions and, 602-603  
 stages in, 603
- Chromosome Y, deletions of, 7
- CI-958, 258
- Cigarette smoking  
 and adult acute leukemia, 9-10  
 and childhood acute leukemia, 5-6
- Ciliary neurotrophic factor, potency of, 291
- Cisplatin, 750  
 in adjuvant therapy, for osteosarcoma, 565  
 for advanced sarcoma, 575  
 in combination chemotherapy, for advanced sarcoma, 576  
 in osteosarcoma therapy, 561-563
- Cisplatin-docetaxel combination therapy, phase II trials of, in NSCLC, 447
- Cisplatin, doxorubicin, ifosfamide, radiation, surgery regimen, for soft tissue sarcoma, 530
- Cisplatin-etoposide combination therapy  
 phase III trial of, for NSCLC, 444  
 randomized trials of, in advanced NSCLC, 446
- Cisplatin-gemcitabine combination therapy, in advanced NSCLC, 448
- Cisplatin-paclitaxel combination therapy  
 for NSCLC, 443-444  
 phase II trial of, 444  
 phase III trial of, 444
- Cladribine, 157
- Clara cell, 388, 389
- Clear cell sarcoma, 520
- Clinical trials, summarizing results of, abbreviations in, 431
- CM101, 209, 211
- Cobalt gray equivalent dose, 690
- Cocaine, soft tissue sarcoma associated with, 508
- Cockayne syndrome, DNA damage repair and, 107-109
- COL-3, 162, 226  
 molecular structure of, 225
- Colony stimulating factor, 294  
 in adult acute myeloid leukemia, 58-59
- Colorectal tumor  
 genetics of, 739-741  
 oncogenes in, 740  
 schematic tumorigenesis model in, 739  
 tumor suppressor gene in, 740-741
- Combination chemotherapy  
 for advanced sarcomas, 575-577  
 for cardiac tumor, 537  
 for soft tissue sarcoma, 530
- Combined modality therapy  
 definitive, in unresectable NSCLC, 433  
 in NSCLC, 429-439
- Complement-mediated cytotoxicity, 177
- Complete response, definition of, 65-66, 70
- Compound 506U78, 233-234
- Compound 776C85, 234  
 molecular structure of, 233
- Computed tomography, in lung cancer, 411-412
- Computer-controlled radiation therapy  
 cone-beam dynamic multileaf collimator intensity modulated, 665-666  
 fan-beam dynamic multileaf collimator intensity modulated radiation therapy-arc based, 664-665  
 multisection, 664  
 x-ray compensating filter intensity modulated, 666
- Computer-controlled radiation therapy treatment machine, 663-666
- Conformal external beam radiotherapy  
 in prostate cancer, 748



- Conformal external beam radiotherapy (*Continued*)  
 increasing biological equivalent dose in, 749-751  
 three-dimensional field in, 748
- Connective tissue disease, malignancy-associated, 360-372
- Cordycepin, 162
- Corticosteroids, in cachexia syndrome, 282
- Corticotrophin releasing hormone, 301-302
- Corticotrophic, 270
- Cost, relative, of proton beam therapy, 694
- CPT-11  
 as second-line NSCLC therapy, 459-460  
 in SCLC, 469-471  
 single-agent, in advanced NSCLC, 442
- Cryptophycin, 162
- CT2584, 209
- Curcumin, 246
- Cuth's profile sign, 347
- Cushing's syndrome, ectopic, neoplasms associated with, 300-302
- Cyclin D, 607
- Cyclin-dependent kinase, 394-396, 603
- Cyclin-dependent kinase inhibitor, 49
- Cyclooxygenase inhibitor, pyrogenic cytokines and, 295-296
- Cyclophosphamide  
 in adult acute lymphoblastic leukemia, 70-72, 70-73  
 for advanced sarcoma, 575  
 in combination chemotherapy, for advanced sarcoma, 576  
 longitudinal risk monitoring following, 110-111  
 metabolism of, 581  
 resistance to, mechanism of, 580-582  
 structure of, 581
- Cyproheptadine, in cachexia syndrome, 284
- Cytarabine, 127-129,  
 in acute promyelocytic leukemia, 94  
 in adult acute lymphoblastic leukemia, 70-73  
 early v late intensification of, 64-65  
 high-dose, in postremission adult acute myeloid leukemia, 62-64  
 intensification of, 64
- Cytarabine, daunorubicin, 6-thioguanine regimen, in adult acute myeloid leukemia, 59-62
- Cytarabine, 6-thioguanine regimen, postremission, 63-64
- Cytarabine ocfosfate, 157
- Cytochrome P450 enzyme, 110
- Cytogenetics  
 in childhood acute lymphocytic leukemia, 84-86  
 overview of, 17
- Cytokeratin, soft tissue sarcoma and, 516
- Cytokine(s), 278-279  
 acute phase responses and, 292  
 in adult acute myeloid leukemia, 58-59  
 biological properties of, 293  
 circulating, 295  
 intrinsic production of, 292-293  
 potency of, 291  
 pyrogenic, 288-291  
 from solid tumors, 294-295
- Cytomegalovirus, 136
- Cytosine arabinoside, daunorubicin regimen, 58
- Cytotoxic agent(s)  
 antigen-specific, 173-186
- Cytotoxic agent(s) (*Continued*)  
 in development, 153-155  
 from marine sources, 158  
 from microbial sources, 158-159  
 from nature, 156-163  
 new, 153-155  
 newly marketed, 157  
 from plant sources, 156-158  
 as radiation sensitizer, 426  
 supply of, 160-162
- Dacarbazine  
 activation of, 583  
 for advanced sarcoma, 575  
 in combination chemotherapy, for advanced sarcoma, 576  
 resistance to, mechanism of, 582
- Dacarbazine, mesna, doxorubicin, ifosfamide regimen, for cardiac tumor, 537
- Dactinomycin, in acute lymphoblastic leukemia, 71-72
- Daunorubicin  
 in acute lymphoblastic leukemia, 70-72  
 in acute promyelocytic leukemia, 94
- Daunorubicin, cytarabine, 6-thioguanine regimen, in adult acute myeloid leukemia, 59-62
- Daunorubicin, cytosine arabinoside regimen, 58
- Dehydroepiandrosterone, 241, 243, 247
- DEK gene, 40
- Delta-9-tetrahydrocannabinol, in cachexia syndrome, 284
- Deoxycytosine, 162
- Dermal deposition, 335-336
- Dermatitis  
 clinical characteristics of, 338  
 patient workup in, 339
- Dermatitis herpetiformis, 356-357  
 clinical characteristics of, 338  
 patient workup in, 339
- Dermatomyositis  
 clinical characteristics of, 340  
 malignancy-associated, 348, 356  
 patient workup in, 341
- Dermatosis, neutrophilic, differential diagnosis of, 342
- Desmin, soft tissue sarcoma and, 516-517
- Destruction box, 605
- Dexamethasone, in adult acute lymphoblastic leukemia, 71-73
- Dexamethasone, methotrexate, vincristine, asparaginase regimen, in adult acute lymphoblastic leukemia, 74
- Dexverapamil, for soft tissue sarcomas, 587
- Didemin B, 158
- Diet  
 carotenoids in, 404-405  
 in cancer prevention, 248-249  
 retinoid intake in, 404  
 vitamin A intake in, 404
- 2-Difluoromethylornithine, 246, 247, 248
- Digital clubbing, 340, 346, 352-353  
 determination of, 347
- Dioxin, soft tissue sarcoma associated with, 506-507
- DNA damage, defective repair of, inherited disorders associated with, 107
- DNA damage checkpoint, 607-608  
 operational steps of, 608



- DNA damage response, 612  
 DNA topoisomerase II inhibitor, 6  
 Docetaxel, 157  
   for advanced sarcoma, 575  
   in NSCLC, 446-447  
   phase II trials of, in advanced NSCLC, 441  
   in SCLC, 469  
   as second-line NSCLC therapy, 456-458  
   single-agent, phase II trials of, 447  
 Docetaxel-cisplatin combination therapy, phase II trials of, in NSCLC, 447  
 Dolastatin, 158  
 Dolastatin 10, 162, 231  
   molecular structure of, 232  
 Dose-volume histogram  
   in brachytherapy, 703-704  
   for cylindrical implant, 704  
   for proton beam therapy, 688, 689  
 Down syndrome  
   acute leukemia and, 4  
   childhood acute lymphocytic leukemia and, 87  
 Doxorubicin  
   for advanced sarcoma, 575  
   in adult acute lymphoblastic leukemia, 70-73  
   in combination chemotherapy, for advanced sarcoma, 576  
   longitudinal risk monitoring following, 110-111  
   in osteosarcoma therapy, 561-563  
   resistance to, mechanism of, 584-586  
   structure of, 584  
 Doxorubicin, cisplatin, ifosfamide, radiation, surgery regimen, for soft tissue sarcoma, 530  
 Doxorubicin, mesna, ifosfamide, dacarbazine regimen, for cardiac tumor, 537  
 Drug design  
   protein structure-based, 164-172  
   scoring of, 170  
 Drug resistance  
   in osteosarcoma, 569  
   in sarcoma therapy, 580-591  
 Drug(s)  
   antigen-specific, 173-186  
   in development, 153-155  
   from marine sources, 158  
   from microbial sources, 158-159  
   from nature, 156-163  
   new, 153-155  
   newly marketed, 157  
   from plant sources, 156-158  
   supply of, 160-162  
 Drug-sensitivity testing, 86  
 DSRCT, 520-521  
 DX-52-1, 162, 226  
   molecular structure of, 227  
 Dye, hair, and adult acute leukemia, 10  
 Early growth response-1, 634  
 Ecteinascidin, 158, 162, 743  
 Edatrexate, for advanced sarcoma, 575  
 Eicosapentaenoic acid, 279  
 Elderly patient(s)  
   acute lymphoblastic leukemia in, 78-79  
   Elderly patient(s) (Continued)  
     incidence of, 485  
     oral etoposide for, 487-488  
     outcome in, 486  
     SCLC in, 484-491  
     treatment in, 486-488  
     treatment recommendations in, 488-489  
 Electrical impedance, tissue, measurement of, 619, 621  
 Electromagnetic fields, and childhood leukemia, 5  
 Electronic portal imaging, 666-667  
 Ellagic acid, 6  
 Ellipticine, 162  
 Elliptinium, 157  
 Encephalitis, paraneoplastic limbic, 326  
 Encephalomyelitis, paraneoplastic, clinical findings in, 322  
 Endocrine syndrome  
   ectopic, 299-300  
   of cancer, 299-317  
 Endocrine tumor, 266  
 Endometrial cancer, high-dose-rate brachytherapy in, 697-698  
 Endoscopic ultrasonography, in lung cancer, 416-417  
 Enneking staging system, for sarcomas, 593-594  
 Environmental factors  
   adult acute leukemia and, 9  
   soft tissue sarcoma and, 508  
 Eosinophilic fasciitis, 366  
 Epidermal growth factor, 391-392  
 Epidermal growth factor receptor, 391-393  
 Epipodophyllotoxin, 157  
 Epirubicin  
   for advanced sarcoma, 575  
   in combination chemotherapy, for advanced sarcoma, 576  
 Epithelial membrane antigen, soft tissue sarcoma and, 516  
 ERG gene, 40  
 Erythema, reactive, 343, 354-355  
 Erythema annulare centrifugum, 354-355  
 Erythema gyratum repens, 347, 354-355  
 Erythrocytosis, 271  
   paraneoplastic-associated, 330  
   tumors associated with, 309  
 Erythroderma  
   clinical characteristics of, 338  
   patient workup in, 339  
 Erythromelalgia  
   clinical characteristics of, 338  
   patient workup in, 339  
 Erythropoietin, 270  
   tumor-produced, 308-309  
 Escherichia coli, 133  
 Estramustine, 750  
 Estrogenic compound, soft tissue sarcoma associated with, 507-508  
 Etanidazole, 750  
 ETO gene, 37  
 Etoposide  
   acute myeloid leukemia associated with, 105-107  
   in adult acute myeloid leukemia, 59-62  
   in combination chemotherapy, for advanced sarcoma, 576  
   oral, in elderly SCLC patients, 487-488  
   for soft tissue sarcomas, 586-587

- Etoposide-cisplatin combination therapy  
   phase III trial of, for NSCLC, 444  
   randomized trials of, in advanced NSCLC, 446  
 ETS family member translocations, 40  
 Ewing's sarcoma, recurrent chromosomal translocations in, 519-520  
 Excision biopsy, v needle biopsy, in soft tissue sarcoma, 595  
 External beam radiation therapy, 715  
   colorectal, 721  
   in gynecologic cancer, 722  
   sequencing of, in treatment, 716  
 Extraskelatal myxoid chondrosarcoma, 521  
  
 F-18-fluorodeoxyglucose, 414  
 Factor VIII-related antigen, soft tissue sarcoma and, 517-518  
 Familial monosomy 7, acute leukemia and, 4  
 Family, cancer, 403  
 Fanconi anemia, acute leukemia and, 4  
 Fast neutron radiotherapy  
   centers for, 682  
   clinical trials of, 679-680  
   dose response curve with, 682  
   in radiation oncology, 676-683  
   relative indications for, 681  
 18FDG, in tumor imaging, 648-650  
 18FDG-PET, oncologic applications of, 650  
 Fetal loss, and childhood acute leukemia, 5  
 Fever, 288-298  
   hypothalamic, 290  
   of paraneoplastic origin, 296  
   tumor, 266  
 Fibroblast growth factor, 207  
 Field cancerization, 402-403  
 Finasteride, 247  
 Flavonoids, 6  
 Flavopiridol, 162, 221  
   molecular structure of, 222  
 Flk-1, 204  
 Florid cutaneous papillomatosis, 351-352  
   clinical characteristics of, 340  
   patient workup in, 341  
 Flt-1, 204  
 Fluasterone, 246  
 Fludarabine, 157  
 Folic acid, 247  
 Follicle stimulating hormone, 306-307  
 Food aversion, 280  
 Formestane, 157  
 Fowler's solution, soft tissue sarcoma associated with, 507-508  
 FR901228, 162, 224-225  
   molecular structure of, 224  
 Fractionation therapy, 424-425  
 French-American-British subtype, in acute myeloid leukemia, 21-22  
 Friend leukemia virus transforming sequence, 519  
 Fumagillin, 209  
 Fungal infection, following acute leukemia therapy, 134-135  
 Fungal pathogens, 133  
*Fusarium*, 135  
  
 G-protein, 393  
 G1 checkpoint, 608-610  
 G2 phase checkpoint, 611-612  
 G3139, 193  
 GADD45, 108  
 Gallium 67 citrate, in tumor imaging, 646  
 Gallium 67 scan, 644  
 Gallium 67 whole body scan, 643  
 Gamma Knife, 707-708  
 Gamma Unit  
   Model B, 708  
   Model U, 708  
 Gastrin-releasing peptide, 391  
 Geladnamycin, 162  
 GEM-91, 192, 194  
 Gemcitabine  
   in combination therapy, for NSCLC, 448  
   in NSCLC, 447-448  
   in SCLC, 469  
   single-agent, 442  
 Gemcitabine-cisplatin combination therapy, in advanced NSCLC, 448  
 Gene amplification, 49  
 Gene therapy  
   pro-drug converting enzyme, 635-636  
   with radiation-enhanceable promoters, 636-638  
 Genetic abnormalities  
   in adult acute leukemia, 7  
   in childhood acute leukemia, 5  
 Genetic factors  
   in adult acute leukemia, 7  
   soft tissue sarcoma and, 508-509  
 Genetic syndrome, in childhood acute leukemia, 4  
 Genistein, 246, 6  
 Genodermatosis  
   characteristics of, 337  
   paraneoplastic syndrome and, 336  
 GG167, 166  
 GG211, 162  
 Glomerular disease, 373-376  
 Glomerulonephritis, rapidly progressive, 375-376  
 Glomerulopathy  
   minimal change, 374-375  
   paraneoplastic, 375  
 Glossypol, 162  
 Glucagonoma syndrome, 355  
 Glutathione, 581-582  
   increased concentration of, 583  
 Glutathione detoxification system, 405  
 Glutathione S-transferases, 109-110, 581-582  
 Glutathione synthesis, 246  
 Glycinamide ribonucleotide formyltransferase  
   antifolate inhibitor of, 169  
   inhibitor of, 168-169  
 GM6001, 209  
 Goldie-Coleman hypothesis, 465-466, 751-752  
 Gonadotropin releasing hormone agonist treatment, 307  
 Gottron's papules, 347, 356  
 Gout, 368  
 GPS0193, 194  
 Graft-versus-leukemia, 120-121

- Granulocyte colony-stimulating factor  
in acute myeloid leukemia, 126-131  
biologics and, 136-137  
longitudinal risk monitoring following, 110-111  
for osteosarcoma, 568
- Granulocyte-macrophage colony-stimulating factor  
in acute myeloid leukemia, 124-131  
biologics and, 136-137
- Growth factor, 391  
in acute myeloid leukemia, 124-131  
biologics and, 136-137  
clinical studies of, 125, 129  
hematopoietic, 77-78  
priming with, 127-130
- Growth hormone, cancer-produced, 308
- Growth hormone releasing hormone, cancer-produced, 308
- Growth-arrest DNA damage-inducible gene, 108
- Gycophorin A somatic mutation assay, 109-110
- Hair dye, and adult acute leukemia, 10
- Halichondrin B, 158, 162  
supply of, 161-162
- HD37-dgA, 180-181
- Head and neck sarcoma, 530-531
- Hematological paraneoplastic syndrome, 329-333  
common, 330
- Hematopoietic growth factor  
in acute myeloid leukemia, 124-131  
in adult acute lymphoblastic leukemia, 77-78  
biologics and, 136-137  
priming with, 127-130  
supportive use clinical studies of, 125
- Hemorrhage, paraneoplastic-associated, 332-333
- Hepatosplenic candidiasis, 135
- HER2-neu, 391-393
- Hereditary nonpolyposis colorectal cancer syndrome, 247, 395
- Herpes group viruses, 133
- Herpes zoster, soft tissue sarcoma associated with, 508
- HHF35, soft tissue sarcoma and, 517
- High-dose-rate brachytherapy  
endobronchial, 697  
in endometrial cancer, 697-698  
in prostate cancer, 697
- Histiocytic marker, soft tissue sarcoma and, 517
- Histogram, dose-volume, in brachytherapy, 703-704
- Histoplasma infection, 415
- HIV, soft tissue sarcoma associated with, 508
- Holmium 166 Chitosan complex, 642, 643-644
- Holmium 166 Chitosan macroaggregated albumin paste, 644
- Homeobox gene, 105
- Homoharringtonine, 157
- Hormone  
glycoprotein, 273  
precursors, of cancers, 299-300  
protein, 299-300
- HPRT mutant frequency assay, 109-110
- HRAS1 minisatellite locus, 403
- HRX gene, 48
- HuD, expression of, 320
- Human chorionic gonadotropin, 306-307
- Human error  
in brachytherapy, 698-699  
classification scheme for, 699
- Human thyrotropin, 306-307
- Humoral hypercalcemia of malignancy, 390
- Hydrazine sulfate, in cachexia syndrome, 284
- Hydroxyethylene diphosphonate therapy, 641
- Hypercalcemia, 267  
cancer and, 302-304  
cancer-associated, mechanism of, 305
- Hyperfractionation, 424-425
- Hypermetabolism, cancer patients and, 277-278
- Hyperthermia  
in drug resistance, 621-622  
mild temperature, and tumor oxygenation, 626-632
- Hyperthermia biology, developments in, 621-623
- Hyperthermic treatment  
of malignant disease, 616-625  
phase III clinical trial results of, 616-617
- Hypertrichosis lanuginosa acquisita, 340, 353
- Hypertrophic osteoarthropathy, 369
- Hypertrophic pulmonary osteoarthropathy, 353
- Hypoglycemia  
cancer-associated, 304-306  
neoplasms associated with, 305
- Hypokalemia, in cancer-induced Cushing's syndrome, 302
- Hypnatremia, 376-377
- Hypophosphatemia, cancer-produced, 309-310
- Hypothalamic syndromes, 290
- Hypouricemia, 377
- i(12)(p10), 21
- Ibuprofen, 246
- Ichthyosis  
clinical characteristics of, 338  
patient workup in, 339
- ICRF-187, 106
- Idarubicin, 157  
in adult acute myeloid leukemia, 59-62  
structure of, 584
- idic(X)(q13), 20
- Idiopathic inflammatory myopathy, 363-365  
onset of, 364
- Ifosfamide  
for advanced sarcoma, 575  
in adjuvant therapy, for osteosarcoma, 564, 567-568  
in combination chemotherapy, for advanced sarcoma, 576  
metabolism of, 581  
resistance to, mechanism of, 580-582  
in SCLC, 469  
structure of, 581
- Ifosfamide, doxorubicin, cisplatin, radiation, surgery regimen, for soft tissue sarcoma, 530
- Ifosfamide, mesna, doxorubicin, dacarbazine regimen, for cardiac tumor, 537
- Immunohistochemistry, in soft tissue sarcoma, 515-516
- Immunologic defects, soft tissue sarcoma and, 509
- Immunophenotype, in childhood acute lymphocytic leukemia, 83-84
- Immunosuppression, therapeutic, soft tissue sarcoma associated with, 509

- Immunotherapy, for osteosarcoma, 569  
 Immunotoxin, 179-182  
 Inclusion body myositis, 363  
 Indinavir, 166  
 Indole-3-carbinol, 246  
 Infants, acute leukemia in, 6-7  
 Infection  
   following acute leukemia therapy, 132-140  
   following host neutropenia, 132-133  
 Influenza, 136  
 Insulin-like growth factor, 391  
   for osteosarcoma, 569  
 Insulin-like growth factor I, 305, 391  
 Insulin-like growth factor II, 271, 305-306  
 Intensity modulated conformal therapy, with inverse planning, 709  
 Intensity modulated radiation therapy, 655, 664-665  
 Interferon, tumor necrosis factor, melphalan regimen, with isolated limb perfusion, 550  
 Interferon gamma-1a, 157  
 Interferon-alpha, 291  
 Interferon-beta, 291  
 Interferon-inducible protein 10, 211  
 Interleukin-1, 279  
   pyrogenic effects of, 291-292  
 Interleukin-1 alpha, 291  
 Interleukin-1 beta, 291  
 Interleukin-6, 291, 296  
   pyrogenic effects of, 291-292  
 Interleukin-12, 209, 211  
 International Bone Marrow Transplant Registry, 73  
 Internet, for radiation oncology, 667-668  
 Intraepithelial neoplasia, 244  
 Intraoperative electron radiation therapy  
   colorectal, 719, 721  
   dose-limiting structures in, 717-718  
   gastric, 720-721  
   gynecologic, 723-724  
   in gynecologic cancer, 722  
   irradiation doses in, 716-717  
   mobile, 728  
   patient selection criteria for, 716  
   pelvic, clinical peripheral neuropathy characteristics with, 718  
   rationale for, 715-716  
   sequencing of, in treatment, 716  
   surgery with, in gastric cancer, 720  
   technical aspects of, 716  
   technique in, 716-717  
   tolerance in, 717-718  
 Intraoperative high-dose-rate brachytherapy  
   rationale for, 715-716  
   technical aspects of, 717  
 Intraoperative irradiation  
   in bladder cancer, 723  
   status of, 715-731  
 Intraoperative radiation therapy  
   colorectal, 721-723  
   for genitourinary malignancies, 725  
   future possibilities for, 727-729  
   in pancreas, 718-720  
 Intraoperative radiation therapy (*Continued*)  
   pediatric, 726  
   potential investigational schemas for, 727  
   in retroperitoneal soft tissue sarcoma, 724-725  
 inv(14)(q11q32.1), 52  
 inv(14)(q11q32.3), 52  
 inv(14:14)(q11q32.1), 52  
 inv(16), acute myeloid leukemia survival and, 27  
 inv(16)(p13q22), 39-40  
 Invasiveness, in paraneoplastic syndromes, 269-270  
 Iodine 131-lipiodol, 642  
 Iodine 131-MIBG therapy, of neuro-endocrine tumors, 644  
 Ipomeanol, 157, 162  
 Irinotecan, 157  
   in combination therapy, 449  
   in NSCLC, 449-450  
 Iron-dextran injection, soft tissue sarcoma associated with, 507-508  
 ISIS 2105, 194  
 ISIS 2922, 194  
 ISIS 3521, 196  
 Isolated limb perfusion, 547-548, 550  
 Isolated limb perfusion, tumor necrosis factor alpha, chemotherapy regimen, for extremity soft tissue sarcoma, 547-555  
 Isotretinoin, 402  
 4IW/CL, 22-23  
 6IW/CL, 22-23  
 Jaspamide, 162  
 Juxtaglomerular apparatus, tumors of, 311  
 K-ras oncogene, 403  
 Karyotype  
   as prognostic factor, in acute myeloid leukemia, 22-23  
   normal, 17-18  
 Keyhole limpet hemocyanin, 174  
 Kidney, paraneoplastic syndromes of, 373-381  
 Kinase cascade  
   leading to DNA replication, 604  
   leading to mitosis, 605  
*Klebsiella pneumoniae*, 133  
 Klinefelter's syndrome, acute leukemia and, 4  
 Kostmann granulocytic leukemia, acute leukemia and, 4  
 KRN5500, 223-224  
 L-alanine, 162  
 Lambert-Eaton myasthenic syndrome, 322-323  
 Lamellarin, 162  
 Langerhans' cell histiocytosis, acute leukemia and, 4  
 Lead compound, design of, 165  
 Lean body mass, 277-278  
 Leptin, 267  
 Leukemia, 120-121  
   acute myelogenous, 290, 293  
   chronic, 294  
   chronic myelogenous, 293-294  
   minimal residual disease in, 52-53  
   secondary, 103-113  
 Leukemogenesis, DNA damage and, 107-109  
 Leukocytes, abnormal counts of, 21

- Leukocytoclastic vasculitis  
  clinical characteristics of, 338  
  patient workup in, 339
- Leukocytosis, paraneoplastic-associated, 330-331
- Li-Fraumeni syndrome, soft tissue sarcoma associated with, 508-509
- Light chain, nephrotoxicity of, 378
- Limb, soft tissue sarcoma of, 548-554
- Limbic encephalitis, paraneoplastic, 326
- Linear accelerator  
  dedicated, 708-709  
  modified, 708
- Lipoprotein lipase, 278
- Liposarcoma  
  myxoid, 521-522  
  round cell, 521-522
- LMB-1, 179
- LMB-2, 180
- LMB-7, 179-180
- Lobectomy, in NSCLC, 420-421
- Longitudinal monitoring, of high-risk populations, 110-111
- Lovibond's profile sign, 346
- LR-3001, 193, 196-197
- LU 103793, 162
- Lung cancer  
  biology of, 388-401  
  chemoprevention and, 402-410  
  CT in, 411-412  
  endoscopic ultrasonography in, 416-417  
  genomic instability in, 395  
  growth of, nicotine and, 392  
  imaging of, 411-418  
  incidence of, 388, 402  
  introduction to, 387  
  molecular biology of, 391  
  MRI in, 412-413  
  oncogene genetic damage in, 392  
  oncogene lesions in, 393-394  
  PET in, 414-416  
  telomeres in, 395  
  treatment of, second lung cancer following, 492-499  
  tumor suppressor genes in, 393-394, 394-396
- Lupus erythematosus, systemic, 365
- Lurotorecan, 162
- Luteinizing hormone, 306-307
- Lycopene, 246
- Lymphedema, soft tissue sarcoma and, 509
- Lymphoma, 294
- Lymphomatoid granulomatosis, 368
- Lymphoscintigraphy, 652
- M phase promoting factor, 603
- M protein, 378
- Magnetic resonance imaging  
  of chemical shift, 620  
  in lung cancer, 412-413
- Major histocompatibility complex antigen, type I, 389
- Malignant ectomesenchymoma, 520
- Marijuana, soft tissue sarcoma associated with, 508
- Marimastat, 209-210
- Matrix metalloprotease, 208-209  
  angiogenesis and, 206  
  inhibitors of, 169-170
- Maximum tolerated dose, 259
- Maximum tolerated systemic exposure, 259
- mec-1 gene, 108
- Medicinal agent, soft tissue sarcoma and, 507-508
- Medroxyprogesterone acetate, in cachexia syndrome, 282
- Megestrol acetate, in cachexia syndrome, 282
- mei-41 gene, 108
- Melatonin, in cachexia syndrome, 285
- Melphalan, tumor necrosis factor regimen, with isolated limb perfusion, 550
- Melphalan, tumor necrosis factor, interferon regimen, with isolated limb perfusion, 550
- Membranous nephropathy, 373-374
- Meningioma, proton beam therapy in, 692-693
- Mercaptopurine, in acute lymphoblastic leukemia, 71-72
- Mesna, doxorubicin, ifosfamide, dacarbazine regimen, for cardiac tumor, 537
- Metabolic syndrome, of cancer, 299-317
- Metallothionein, 583
- Metastasis, angiogenesis and, 204
- Metastast, 209
- Methotrexate  
  in acute lymphoblastic leukemia, 70-72  
  in combination chemotherapy, for advanced sarcoma, 576  
  in osteosarcoma therapy, 561, 566-567
- Methotrexate, vincristine, asparaginase, dexamethasone regimen, in adult acute lymphoblastic leukemia, 74
- Metoclopramide, in cachexia syndrome, 283
- MGI 114, 162
- MIC2, soft tissue sarcoma and, 518
- Microbial agents, cytotoxic, 158-159
- Microenvironment, of tumor, 622-623
- Microvascular disease, 376
- Mild temperature hyperthermia  
  study design for, 626-626  
  study results in, 627-629  
  tumor oxygenation and, 626-632
- Miltefosine, 157
- Mini-chromosome maintenance protein, 603-604
- Minimal change glomerulopathy, 374-375
- Minimal residual disease  
  in acute promyelocytic leukemia, 98  
  in acute lymphoblastic leukemia, 80  
  in leukemia, 52-53
- Mitogen, 393
- Mitogenesis, 241-242
- Mitosis, kinase cascade leading to, 605
- Mitoxantrone  
  for adult acute lymphoblastic leukemia, 70-72  
  for adult acute myeloid leukemia, 59-62
- MLL gene, 48-49  
  at 11q23, 5  
  in infants, 6
- MMC, as second-line NSCLC therapy, 460
- Mobetron, 728
- Modeling technique, for noninvasive thermometry development, 619-621
- Molecular epidemiology, quantitation in, 109-110

- Monoclonal antibody(ies)  
   in cancer therapy, 177-179  
   in clinical trials, 652  
   new approaches to, 178  
   unconjugated, 177
- Monoclonal Ig deposition disease, 379
- MRI, *see* Magnetic resonance imaging
- MSH2, 395
- MTS1, 49
- MTS2, 49
- Mucocutaneous paraneoplastic syndrome, 267, 334-359  
   associated with hematologic malignancies, 335-349  
   clinical characteristics of, 338  
   genodermatoses and, 336  
   patient workup in, 339  
   solid tumor-associated, clinical characteristics of, 340
- Multidrug resistance, 585-586
- Multiple myeloma, 294, 378-379
- Mumps, soft tissue sarcoma associated with, 508
- Musculoskeletal system, cancer effects on, 369
- Mutagenesis, 241-242, 244
- Mutation, point, 49
- Myelodysplastic syndrome, following alkylating agents, 103-104
- Myeloma kidney, 378
- Myoclonus, 325-326
- MyoD1, soft tissue sarcoma and, 517
- Myotonia, 324
- N-acetyl-L-cysteine, 246
- N-acetylcysteine, 405
- N'-nitrosomornicotine, 392
- Necrolytic migratory erythema, 354-355  
   clinical characteristics of, 340  
   patient workup in, 341
- Needle biopsy, v excision biopsy, in soft tissue sarcoma, 595
- Nelfinavir, 166
- Nervous system, paraneoplastic syndromes affecting, 318-328
- Neural antigen, soft tissue sarcoma and, 517
- Neural crest, 299-300
- Neuroendocrine marker, 389
- Neurofibromatosis, acute leukemia and, 4
- Neuroleptic syndrome, 288
- Neurological paraneoplastic syndromes  
   antineuronal antibodies associated with, 321  
   autoantibodies in, 320-321  
   general considerations of, 318-319  
   pathogenesis of, 319  
   pathology of, 319-320  
   treatment of, 321-322  
   types of, 319
- Neuromyotonia, 324
- Neuropeptide Y, 278
- Neutron, in cancer therapy, 672-685
- Neutropenia  
   host, infectious complications following, 132-140  
   paraneoplastic-associated, 331
- Neutrophilic dermatosis, 336-337  
   differential diagnosis of, 342
- Nevoid basal cell carcinoma syndrome, soft tissue sarcoma associated with, 509
- Nicotine, lung cancer growth and, 392
- Nitrosamino ketone, nicotine-derived, 392
- Non-small cell lung cancer, 389-391  
   active single-agent chemotherapy in, 441  
   advanced, chemotherapy for, 440-454  
   carboplatin-paclitaxel randomized trials in, 446  
   cisplatin-etoposide phase III trials in, 444  
   cisplatin-etoposide randomized trials in, 446  
   cisplatin-paclitaxel phase III trials in, 444  
   combination chemotherapy phase III trials in, 444  
   combined modality therapy of, 429-439  
   cooperative group studies in, 446  
   CPT-11 second-line therapy in, 459-460  
   current chemotherapy in, 441  
   docetaxel second-line therapy in, 456-458  
   early-stage, surgery for, 419-422  
   first-line chemotherapy for, 455-456  
   future chemotherapy in, 450-451  
   gemcitabine in, 447-448  
   gemcitabine-cisplatin therapy in, 448  
   irinotecan combination therapy in, 449  
   irinotecan in, 449-450  
   limited resection v lobectomy in, 420-421  
   lymph node sampling v resection in, 421-422  
   lymph node status in, 420  
   MMC second-line therapy in, 460  
   paclitaxel for, in combination with other drugs, 446  
   paclitaxel in, 442-445  
   paclitaxel second-line therapy in, 458-459  
   paclitaxel-carboplatin combination therapy for, 444-445  
   paclitaxel-carboplatin phase II trials in, 445  
   paclitaxel-cisplatin combination therapy for, 443-444  
   patient subgrouping in, 430  
   phase II cisplatin-docetaxel trials in, 447  
   phase II docetaxel trials in, 441  
   phase II paclitaxel trials in, 441  
   phase II single-agent docetaxel trials in, 447  
   phase II trials in, 432  
   postoperative therapy of, 432  
   preoperative therapy trials in, 433  
   previously-treated, paclitaxel in, 443  
   recurrent, management strategies for, 455-462  
   second-line chemotherapy for, 456-460  
   second-line therapy literature for, 457  
   single-agent CPT-11 in, 442  
   single-agent gemcitabine in, 442  
   stage III, preoperative therapy for, 430-432  
   staging of, current problems in, 429-430  
   surgical candidates in, 419-420  
   survival in, 420  
   thoracoscopy in, 421  
   treatment of, second lung cancer following, 493-495  
   unresectable, definitive combined modality therapy for, 433  
   unresectable stage III, combined modality therapy trials in, 434, 435  
   unresectable stage IIIA-IIIB, radiation therapy in, 423-428  
   vindesine second-line therapy in, 460  
   vinorelbine in, 448-449  
   vinorelbine second-line therapy in, 459  
   VP-16 second-line therapy in, 460
- Non-steroidal anti-inflammatory drug, 241, 243, 247, 250  
   as antipyretic, 296-297

- Nonsuppressible insulin-like activity soluble in acid-ethanol, 305  
NSC654261, 231  
NSCLC, *see* Non-small cell lung cancer  
NUP214, 40  
Nutrition  
    counseling about, 282  
    total parenteral, 281  
  
O6-alkyltransferase, 582  
O6-benzylguanine, 228-229  
    molecular structure of, 227  
OddC, 234-235  
    molecular structure of, 233  
OIH, 1, 25, 304, 309  
OL(1)p53, 193-194  
Oltipraz, 246, 247  
Oncogene  
    in colorectal tumors, 739-740  
    in lung cancer, 393-394  
    radiosensitivity and, 426-427  
Oncogenic osteomalacia, 309-310  
Ontogeny  
    apoptosis and, 269  
    molecular, 273  
    tissue, 273-274  
Opsoclonus, 325-326  
Organomegaly, 21  
Origin recognition complex, 603-604  
Orthotopic cardiac transplantation, for cardiac tumors, 534-539  
Osteoarthritis  
    hypertrophic, 369  
    hypertrophic pulmonary, 340, 353  
Osteoclast, 267  
Osteomalacia, oncogenic, 309-310  
Osteosarcoma  
    adjuvant therapy in, 563  
    chemotherapy dose intensification for, 569  
    drug resistance in, 569  
    immunotherapy for, 569  
    insulin-like growth factor for, 569  
    multidisciplinary collaboration and, 594  
    non-metastatic, chemotherapy in, 561-571  
    Rosen T10 regimen for, 563  
    soft tissue sarcoma associated with, 509  
    soft tissue sarcoma similarities to, 592-593  
    survival in, 562  
  
P15, 49  
P16, 49  
P30-32, soft tissue sarcoma and, 518  
p53, 193-194, 394-396  
    induction of, 609  
p53 tumor suppressor protein, 108  
Paclitaxel, 157  
    for advanced sarcoma, 575  
    in combination regimens, for NSCLC, 443, 445, 446  
    in NSCLC, 442-445  
    phase II trials of, in advanced NSCLC, 441  
    in previously-treated NSCLC patients, 443  
    in SCLC, 469  
  
Paclitaxel (*Continued*)  
    as second-line NSCLC therapy, 458-459  
    for soft tissue sarcomas, 587  
Paclitaxel-carboplatin combination therapy  
    for NSCLC, 444-445  
    phase II trial of, in NSCLC, 445  
    randomized trials of, in advanced NSCLC, 446  
Paclitaxel-cisplatin combination therapy  
    for NSCLC, 443-444  
    phase II trial of, 444  
    phase III trial of, 444  
Paget's disease  
    clinical characteristics of, 340  
    extramammary, 345, 351  
    pathologic differential diagnosis of, 351  
    patient workup in, 341  
Palliative therapy, in SCLC, 468-469  
Palmar fasciitis, 340, 354, 366  
Pancoast tumor, 413, 414  
Pancreas, intraoperative radiation therapy in, 718-720  
Pancreatic peptide Y, 278  
Panniculitis, 368  
Papulosquamous disorder, 338-343, 349-352  
Para-xylylselenocyanate, 249  
Parainfluenza, 136  
Paraneoplastic cerebellar degeneration, 324-325  
Paraneoplastic pemphigus, 345, 349  
    clinical characteristics of, 338  
    diagnostic criteria for, 350  
    patient workup in, 339  
Paraneoplastic phenomena, 390-391  
Paraneoplastic syndrome(s)  
    affecting nervous system, 318-328  
    autocrine mediators and, 274  
    autoimmune, 267  
    bystander effect and, 274  
    clinical importance of, 265  
    definition of, 265-268  
    endocrine mediators and, 274  
    future directions in, 267-268  
    hematological, 329-333  
    introduction to, 265-267  
    of kidney, 373-381  
    mechanisms of, 269-276  
    mucocutaneous, 334-359  
    paracrine mediators and, 274  
    pathogenic mechanisms associated with, 274-275  
    physiologic mechanisms of, 269-270  
Parathormone, of cancer, 302-304  
Parathormone-related polypeptide, 267  
Parathyroid hormone-related peptide, 390  
Parenteral nutrition, total, 281  
Paris system, 703  
Peacock system, 709  
    multileaf collimator for, 710  
Pegaspargase, 157  
PEITC, 246  
Peldesine, 166  
Pemphigus  
    diagnostic criteria for, 350  
    paraneoplastic, 345, 349



- Pemphigus foliaceus, 349  
 Pemphigus vulgaris, 349  
   clinical characteristics of, 338  
   patient workup in, 339  
 Penclomedine, 227-228  
   molecular structure of, 227  
 Pentosan polysulfate, 209  
 Pentostatin, 157  
 Pentoxifylline, in cachexia syndrome, 284  
 Peptide nucleic acid, 197-198  
 Perillyl alcohol, 162, 246  
 Peripheral blood stem cell transplantation, 118-119  
   in SCLC, 468  
 Peripheral neuropathy, paraneoplastic-associated, 323-324  
 Pesticides, adult acute leukemia and, 9  
 PET, see Positron emission tomography  
 Petrochemical industry, adult acute leukemia and, 9  
 Ph chromosome, presence of, 76-77  
 Phakellistatin, 162  
 Phase I trial  
   alternative design strategies for, 256-260  
   dose escalation schemes in, 255-260  
   model-guided dosing in, 257  
   modified Fibonacci number series in, 256  
   new methodology in, 253-261  
   original Fibonacci number series in, 256  
   patient autonomy in, 259  
   patient selection for, 253-255  
   pharmacokinetically-guided dosing in, 257-258  
   starting dose for, 254-255  
   traditional dose escalation in, 255  
   traditional dose escalation pitfalls, 256  
   variables in, 256  
 Phase II trial  
   of combined modality therapy, for unresectable stage III NSCLC, 434  
   of docetaxel, in advanced NSCLC, 441  
   in NSCLC, 432  
   of paclitaxel, in advanced NSCLC, 441  
   of paclitaxel-carboplatin therapy, in NSCLC, 445  
   of paclitaxel-cisplatin therapy, in NSCLC, 444  
   of single-agent docetaxel, in NSCLC, 447  
 Phase III trial, of combination chemotherapy, in NSCLC, 444  
 Phenethyl isothiocyanate, 405  
 Phenoxycetic acid herbicides, soft tissue sarcoma associated with, 506-507  
 Phosphatidylinositol kinase family, 108  
 Phosphorothioate oligonucleotide, 191  
   clinical trials of, 192-197  
   pharmacokinetics of, 191-192  
   toxicology of, 192  
 Photodynamic therapy, 407  
 Photon radiotherapy, 680  
   fast neutron v, 681  
 Phyllanthoside, 162  
 Piroxicam, 246, 247, 247  
 Pityriasis rotunda, 352  
   clinical characteristics of, 340  
   patient workup in, 341  
 Plants, anticancer agents from, 156-158  
 Platelet factor 4, 209-210  
 Platelet functional disorder, paraneoplastic-associated, 331  
 Platelet transfusion, indications for, 141  
 Platinum agents, 584  
*Pneumocystis carinii* pneumonia, 133  
 Pneumocyte, type II, 389  
 Podophyllin, 6  
 Podophyllotoxin, 157  
 POEMS syndrome, 366  
 Point mutation, 49  
 Polyarteritis, 366  
   malignancy-associated, 344  
 Polyarteritis nodosa, 367  
   clinical characteristics of, 338  
   patient workup in, 339  
 Polymyalgia rheumatica, 367  
 Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes, 366  
 Polypeptide, 273  
 Polyphenol, in cancer prevention, 249  
 Porfimer sodium, 157  
 Positron emission tomography  
   18-FDG, oncologic applications of, 650  
   in lung cancer, 414-416  
 Prednisone, in acute lymphoblastic leukemia, 70-72  
 Preneoplasia, 395-396  
 Profile sign  
   Curt's modified, 347  
   Lovibond's, 346  
 Prognostic factor, in acute lymphoblastic leukemia, 74-75  
 Prognostic marker, in prostate cancer, 746  
 Prolactin, cancer-produced, 310-311  
 Proopiomelanocortin, 300-302  
 Prophylactic cranial radiation  
   efficacy of, 478-479  
   in SCLC, 477-483  
   toxicity associated with, 479-480  
   trial data results in, 478, 479  
 Prostaglandin, of cancer, 303  
 Prostate cancer  
   at-risk patients in, 745-746  
   chemotherapy in, 751-752  
   conformal external beam radiotherapy in, 748  
   conventional radiation therapy in, 749  
   decreasing tumor volume in, 751  
   high-dose-rate brachytherapy in, 697  
   local control in, 746-749  
   prognostic markers in, 746  
   proton beam therapy in, 691  
   protons in, 747-748  
   radiotherapy in, 745-755  
   relative integral dose radiotherapy in, 746-747  
   targeting in, 748-749  
 Prostate-specific antigen, 746  
 Prostate-specific membrane antigen, 746  
 Protein  
   PTH-related, 303-304  
   structure-based drug design, 164-172  
 Protein kinase C, 196  
 Proteoglycan, 279  
 Proto-oncogene, 393  
   in acute leukemia, 7

- Proton beam therapy  
   in astrocytoma, 692  
   in cervical spine sarcoma, 692  
   clinical trial design for, 693-694  
   depth dose curves for, 687  
   dose-volume histogram for, 688, 689  
   future directions in, 694-695  
   in meningiomas, 692-693  
   overview of, 686  
   physics and, 686  
   in prostate cancer, 691  
   in radiation oncology, 686-695  
   relative biological effectiveness of, 690-691  
   relative cost of, 694  
   in retinoblastoma, 692  
   schematic of, 687  
   in skull base sarcoma, 692  
   treatment planning with, 686-690  
   in uveal melanoma, 691-692
- Proton radiosurgery, 693
- Proton radiotherapy, fractionated, normal tissue tolerance of, 693
- Protozoa, 133
- Pruritis  
   clinical characteristics of, 338  
   patient workup in, 339
- Pseudallescheria*, 135
- Pseudomonas aeruginosa*, 133
- PTH-related protein, 303-304
- Purine nucleoside phosphorylase inhibitor, 168
- Pyoderma gangrenosum, 336-338  
   clinical characteristics of, 338  
   lesions of, 344  
   patient workup in, 339
- Pyrogen, endogenous, 290-291
- Pyrogenic cytokines, 288-291  
   acute phase responses and, 292  
   biological properties of, 293  
   from solid tumors, 294-295  
   intrinsic production of, 292-293  
   potency of, 291
- Hq23 abnormalities, 48-49
- QBEND10, soft tissue sarcoma and, 518
- Quercetin, 6
- Quinolones, 6
- Raas gene code, 393
- Rad-3 gene, 108
- Radiation  
   in adult acute leukemia, 8  
   in childhood acute leukemia, 5  
   dose of, 543  
   for soft tissue sarcoma, 505  
   postoperative, 543  
   preoperative, 543
- Radiation, doxorubicin, cisplatin, ifosfamide, surgery regimen, for soft tissue sarcoma, 530
- Radiation oncology, advances in, introduction to, 601
- Radiation oncology informatics, 667
- Radiation therapy  
   altered fractionation in, 424-425  
   conformal dose delivery of, 425-426  
   cytotoxic agent sensitizers in, 426  
   standard, historical results of, 424  
   in unresectable stage IIIA-IIIB NSCLC, 423-428
- Radiation-inducible promoter, 634-635
- Radioactive stent, 704
- Radiogenetic therapy, for local tumor control, 633-638
- Radioimmunosintigraphy, 650-652
- Radioimmunotherapy, 644-646
- Radioisotope  
   in radiation oncology, 639-654  
   in tumor imaging, 646-652
- Radionuclide(s)  
   administration routes for, 640  
   beta-emitting, 640  
   in bone pain palliation, 641-643  
   in thyroid cancer, 63-641  
   for tumor imaging, 643
- Radionuclide therapy, 639-644  
   for cystic tumors, 643-644  
   via intra-arterial infusion therapy, 644  
   for malignant ascites, 643-644  
   via percutaneous intratumoral injection, 644
- Radiosensitivity  
   oncogenes and, 426-427  
   tumor suppressor genes and, 426-427
- Radiosensitizer(s), 750  
   alternative, 426-427  
   cytotoxic agent as, 426
- Radiosurgery  
   proton, 693  
   stereotactic, 707-714
- Radiotherapy  
   altered fractionation in, 750-751  
   conformal external beam, in prostate cancer, 748  
   fast neutron, in radiation oncology, 676-683  
   in prostate cancer, 745  
   for soft tissue sarcoma, 544  
   stereotactic, 707-714  
   three-dimensional conformal, 749
- raf kinase, 195-196
- Rapamycin, 162, 225-226  
   molecular structure of, 225
- Rapidly progressive glomerulonephritis, 375-376
- Raynaud's phenomenon, 365-366  
   chemotherapy-induced, 355  
   clinical characteristics of, 340  
   paraneoplastic, 355  
   patient workup in, 341
- Razoxane, 106
- RB gene, 52
- Rb protein, 394
- Reactive erythema, 343, 354-355
- Rebeccamycin, 162, 226-227  
   molecular structure of, 227
- Rectal cancer  
   adjuvant chemoradiation trial in, 735, 736  
   adjuvant therapy in, 737-739  
   chemoradiation protocol for, 736

- Rectal cancer (*Continued*)  
 clinical staging in, 733-734  
 critical issues in, 732-744  
 future strategies in, 741  
 local treatment in, 739  
 management of, current status of, 734-736  
 surgery field in, tumor outside, 737  
 surgical adequacy in, 736  
 surgical considerations in, 736-739  
 treatment algorithm for, 735  
 tumor fixation in, 733-734  
 tumor implantation in, 737  
 tumor location in, 733  
 tumor mobility in, 733-734
- Rectum, true, 732-733
- Red cell transfusion, indications for, 141-142
- Reflex sympathetic dystrophy syndrome, 366
- Registry, International Bone Marrow Transplant, 73
- Relative biological effectiveness, of protons, 690-691
- Renal cancer, intraoperative radiation therapy for, 725-726
- Renal failure, of multiple myeloma, 378
- Renal syndrome, 267
- Renal tubular obstruction, by tumor products, 377-378
- Renin, cancer-produced, 311
- Replication protein A, 609
- Respiratory syncytial virus, 136
- Resting energy expenditure, 277-278
- Reticulohistiocytosis, multicentric, 340, 353-354
- Retinoblastoma  
 proton beam therapy in, 692  
 soft tissue sarcoma associated with, 509
- Retinoblastoma gene, 301
- Retinoic acid, 246, 247  
 all-trans, 23, 65, 92-102  
 efficacy of, hypothesis for, 93-94  
 in leukemic cell differentiation, 93
- Retinoid, dietary intake of, 404
- Retinol palmitate, 406
- Retinopathy, cancer-associated, 326
- Retroperitoneal tumor, 531
- RFB4-dgA, 180-181
- Rhabdomyosarcoma  
 adjuvant therapy for, 556  
 alveolar, 522
- Rhenium 186 hydroxyethylene diphosphonate chelate, 641
- Rheumatic disease  
 malignancy-associated, 360-372  
 type of, associated with malignancy, 361
- Rheumatoid arthritis, 360-362
- Rheumatologic syndrome, 267
- Rhizoxin, 231  
 molecular structure of, 232
- Risk, longitudinal monitoring of, following epipodophyllotox-  
 ins, 110-111
- Ritonavir, 166
- Rosen T10 protocol, in osteosarcoma, 561-563
- Rubber industry, adult acute leukemia and, 9
- S phase checkpoint, 610-611
- S phase promoting factor, 602-603
- S-allyl-L-cysteine, 246
- S100 protein, soft tissue sarcoma and, 517
- Samarum 153 ethylene diamine tetramethylene phosphoric  
 acid, 641-643
- Saquinavir, 166
- SarCNU, 230-231  
 molecular structure of, 230
- Sarcoma, 620  
 proton beam therapy in, 692  
 research in, 503  
 synovial, 522  
 therapy for, future of, 592-597
- Scar, soft tissue sarcoma associated with, 508
- Schwachman syndrome, acute leukemia and, 4
- SCLC, see Small-cell lung cancer
- Scleroderma, 365-366
- Second cancer, 402  
 following NSCLC therapy, 493-495  
 following SCLC therapy, 495-497  
 preventing, 405-406
- Secondary leukemia, 103-113  
 clinical features of, 104  
 high-risk populations for, 110-111  
 longitudinal risk monitoring in, 110-111  
 molecular pathogenesis of, 103-113
- Selenium, 247, 249
- Sign of Leser-Trelat, 346, 352  
 clinical characteristics of, 340  
 patient workup in, 341
- Skull base sarcoma, proton beam therapy in, 692
- Small-cell lung cancer, 388-389  
 alternating non-cross-resistant chemotherapy in, 465-466  
 alternative brain metastasis therapy in, 480  
 brain metastases in, 477-478  
 chemoradiotherapy in, 470  
 chemotherapy dosing increase in, 466-468  
 chemotherapy duration in, 463  
 chemotherapy randomized trials in, 464  
 current management of, 463-476  
 in elderly patients, 484-491  
 extensive disease, 463-471  
 Goldie-Coldman hypothesis in, 465-466  
 induction dosing intensity in, 467  
 limited disease, 472-473  
 maintenance therapy in, 463-464  
 new agents in, 469-471  
 new approaches in, 465  
 new combination therapy in, 471  
 oral etoposide for, in elderly, 487-488  
 predicting chemotherapy toxicities in, 488  
 prophylactic cranial irradiation in, 477-483  
 stem cell support in, 468  
 therapy recommendations for, in elderly, 488-489  
 treatment of, second lung cancer following, 495-497  
 weekly chemotherapy in, 466
- Smoking  
 adult acute leukemia and, 9-10  
 childhood acute leukemia and, 5-6  
 lung cancer and, 392
- Sodium selenite, 405
- Soft tissue sarcoma  
 adjuvant chemotherapy effect in, 558

## Soft tissue sarcoma (Continued)

- adjuvant therapy for, 556-560
- adult, 556-557
- advanced, chemotherapy for, 572-579
- biopsy of, 527
- brachytherapy for, 528
- chemoradiotherapy for, 544
- chemotherapy schedule for, 558
- clinical management of, 528
- combination chemotherapy efficacy in, 593
- combination chemotherapy for, 575-577
- differential diagnosis of, 515-525
- doxorubicin, cisplatin, ifosfamide, radiation, surgery regimen for, 530
- Enneking staging of, 593-594
- environmental factors and, 508
- epidemiology of, 504-514
- excision biopsy v needle biopsy in, 595
- extremity, isolated limb perfusion, tumor necrosis factor
  - alpha, chemotherapy regimen for, 547-555
- genetic factors and, 508-509
- grading systems in, 593-594
- high-grade, adjuvant trials in, 557
- histological grade in, 542-543
- immunohistochemistry in, 515-516
- immunologic defects and, 509
- incidence of, 504-505
- infectious agents and, 508
- intermediate filaments in, 516-517
- of limb, 548-554
- local control of, 540-546
- local growth characteristics of, 526-527
- local recurrence in, 531
- lymphedema and, 509
- markers in, 517-518
- medicinal agents and, 507-508
- metastatic disease pattern of, 531-532
- metastatic potential of, 526
- molecular genetic changes in, 518-519
- muscle markers in, 517
- neoadjuvant therapy for, 528
- occupational chemicals and, 506-507
- osteosarcoma similarities to, 592-593
- pathological type of, 543-544
- pathology of, 526-527
- patient response in, 573
- physician management of, 594-596
- postoperative care in, 530
- postoperative radiation for, 543
- preoperative radiation for, 529-530
- preoperative therapy for, 529-530
- primary v recurrent, 544
- radiation and, 505
- radiation dose in, 543
- retroperitoneal, intraoperative radiation therapy for, 724-725
- single agent v combination chemotherapy in, 574-577
- single-agent chemotherapy efficacy in, 593
- single-agent chemotherapy for, 575
- size of, 543
- staging in, 593-594
- surgical management of, 526-533

## Soft tissue sarcoma (Continued)

- surgical margin status in, 540-542
- surgical procedures for, 528-529
- therapy for, drug resistance to, 580-591
- therapy timing in, 573-574
- translocations in, 519-520
- treatment modality selection for, 527-528
- Somatostatin, 267
- Sorbusoxane, 157
- Spicamycin, 162, 223
- Sponge, 161
- Spongostatin, 158
- Spongostatin, 158
- SRT, 709
- Stannum 117m diethylene-triamine-penta-acetic acid, 641
- Staurosporine, 162
- Stem cell transplantation
  - allogeneic hematopoietic, 114-118
  - peripheral blood, 118-119
  - preparative regimen for, 119-121
  - umbilical blood, 119
- Stent, radioactive, 704
- Stereotactic irradiation
  - in arteriovenous malformations, 709-710
  - clinical research in, 709-713
  - clinical trial protocols in, 712
  - in functional lesions, 710-711
  - in malignant disease, 711
  - new developments in, 707-714
  - prospective trials of, 711-713
- Stereotactic radiosurgery, 707-714
- Stereotactic radiotherapy, 707-714
- Steroid(s)
  - androgenic-anabolic, soft tissue sarcoma associated with, 507-508
  - precursor, cancer metabolism of, 311
- Stewart-Treves syndrome, soft tissue sarcoma associated with, 509
- Stiff-man syndrome, 324
- Stiff-person syndrome, 324
- Strontium 89 chloride, 641
- Structure-based drug design, 164-172
  - future of, 170-171
- Styrene, 9
- Sulindac sulfone, 246
- Superior sulcus tumor, 413, 414
- Surfactant-associated protein, 389
- Surgery
  - sequencing of, in combined modality treatment, 716
  - in soft tissue sarcoma, 526-533
- Surgery, doxorubicin, cisplatin, ifosfamide, radiation regimen, for soft tissue sarcoma, 530
- Surveillance, Epidemiology and End Results program, 504
- Sweet's syndrome, 336-338, 344, 368
  - clinical characteristics of, 338
  - patient workup in, 339
- Syndrome of inappropriate antidiuretic hormone secretion, 376-377, 390
- Synovial sarcoma, 522
- Systemic lupus erythematosus, 365

- t(1:11)(p32;q23), 35  
 t(1:11)(q21;q23), 35  
 t(1:14)(p33;q11), 50-51  
 t(1:19)(q23;p13), 47-49  
 t(10:11)(p12;q23), 35  
 t(10:14)(q24;q11), 51  
 t(11:14)(p13;q11), 51  
 t(11:14)(p15;q11), 51  
 t(11:17)(q23;q21), 35  
 t(11:19)(q23;p13.1), 35-36  
 t(11:19)(q23;p13.3), 36  
 t(11:V)(q23:V), 52  
 t(12:22)(p13;q11), 40  
 t(12:V)(p12-13:V), 49  
 t(15:17), acute myeloid leukemia survival and, 27  
 t(15:17)(q22;q11), 7  
 t(16:16), acute myeloid leukemia survival and, 27  
 t(16:16)(p13;q22), 39-40  
 t(16:21)(p11;q22), 40  
 t(17:19)(q22;p13), 48  
 t(3:21)(q6;q22), 38  
 t(6:11)(q27;q23), 35  
 t(6:9)(p23;q34), 40  
 t(7:10)(q35;q24), 51  
 t(7:9)(q34;q34.3), 51-52  
 t(8:14)(q24;q11), 50  
 t(8:14)(q24;q32), 47  
 t(8:21), 20  
     acute myeloid leukemia survival and, 27  
 t(8:21)(q22;q22), 37-38, 7  
 t(9:11), acute myeloid leukemia survival and, 27  
 t(9:11)(p22;q23), 35  
 t(9:22)(q24;q11), 48  
 t(9:22)(q32;q11), 48  
 Tamm-Horsfall protein, 378  
 Tamoxifen, 247  
     longitudinal risk monitoring following, 110-111  
 TAP1, 389  
 Taxanes, for soft tissue sarcomas, 587  
 Taxol, 750  
     for soft tissue sarcomas, 587  
 Tea, in cancer prevention, 249  
 Tecogalan, 162, 209-210  
 TEL gene product, 40  
 tel-1 gene, 108  
 Telomere, in lung cancer, 395  
 Temozolomide, activation of, 583  
 Temperature, core, 288  
 Temporal arteritis, 367  
 Teniposide  
     in acute lymphoblastic leukemia, 71-72  
     acute myeloid leukemia associated with, 105-107  
 Thalidomide, 209-210  
 Thallium 201 chloride, in tumor imaging, 646-648  
 Thermal dosimetry, 617-618  
 Thermometry, noninvasive, development of, 619-621  
 Thermotolerance, in treatment outcome, 623  
 Thiocoraline, 162  
 6-Thioguanine, in acute lymphoblastic leukemia, 71-73  
 6-Thioguanine, cytarabine, regimen, postremission, 63-64  
 6-Thioguanine, daunorubicin, cytarabine regimen, in acute myeloid leukemia, 59-62  
 Thiram, 6  
 Thoracoscopy, in NSCLC, 421  
 Thorotrast, 506  
 Three-dimensional conformal radiation therapy, overview of, 655  
 Three-dimensional radiation treatment planning  
     automated computer optimization in, 661-663  
     digitally reconstructed radiographs in, 658  
     dose calculation in, 658-661  
     image segmentation in, 656-658  
     imaging for, 656  
     interactive plan improvement in, 661  
     overview of, 655-656  
     plan optimization in, 661  
 Thrombocytopenia, paraneoplastic-associated, 331  
 Thrombocytosis, paraneoplastic-associated, 331  
 Thrombosis, paraneoplastic-associated, 331-332  
 Thrombospondin-1, 205  
 Thrombotic microangiopathy, 376  
 Thymidylate synthase  
     antifolate inhibitor of, 167  
     inhibitors of, 166-168  
 Thymitaq, 166  
 Thyroid cancer  
     radionuclides in, 640-641  
     well-differentiated, radionuclides in, 639-641  
 Thyroid-stimulating hormone, 271  
 Tirapazamine, 426  
 TLS-FUS gene, 40  
 TNP-470, 162, 209  
 Topotecan, 157  
     for advanced sarcoma, 575  
     in osteosarcoma, 569  
     in SCLC, 469, 471  
 Total parenteral nutrition, 281  
 Transforming growth factor, 293  
 Transfusion, blood  
     alternatives to, 144  
     indications for, 141-142  
     infectious risks of, 142  
     noninfectious risks of, 142-144  
 Transplantation, orthotopic cardiac, 534-539  
 Transrectal ultrasound, 697  
 Trichosporin, 135  
 Tripe palms, 346, 352  
     clinical characteristics of, 340  
     patient workup in, 341  
 Trisomy 8, 7  
 Trisomy 11, 36-37  
 Trisomy 21, 7  
 Trithorax gene, 34, 105  
 Trousseau's syndrome  
     clinical characteristics of, 340  
     patient workup in, 341  
 Tubulin agent, 231  
 Tumor blood flow, hyperthermia modification of, 622-623  
 Tumor blush, 273  
 Tumor factor, 279  
 Tumor fever, 266

- Tumor imaging, 646-652
- Tumor marker
- common, 640
  - in prostate cancer, 746
- Tumor necrosis factor, 291
- pyrogenic effects of, 291-292
- Tumor necrosis factor, melphalan, interferon regimen, with isolated limb perfusion, 550
- Tumor necrosis factor, melphalan regimen, with isolated limb perfusion, 550
- Tumor necrosis factor alpha, 278-279
- isolated limb perfusion, chemotherapy regimen, for extremity soft tissue sarcoma, 547-555
  - potency of, 291
- Tumor oxygenation
- hyperthermia impact on, 621
  - mild temperature hyperthermia and, 626-632
- Tumor suppressor gene, 49, 52
- in lung cancer, 394-396
  - radiosensitivity and, 426-427
- Tumor volume, decreasing, 751
- Tylosis
- acquired, 350
  - clinical characteristics of, 340
  - patient workup in, 341
- UCN-01, 162, 221-222
- Ultrasonography, endoscopic, in lung cancer, 416-417
- Ultrasound backscatter, measurement of, 619
- Umbilical cord transplantation, 119
- Urinary gonadotropin peptide, 307
- Urocortin, 267
- Ursodiol, 246
- Uveal melanoma, proton beam therapy in, 691-692
- Vaccine(s)
- defined antigen, 174
  - investigational new drug, 175
  - for serologic responses, 174
  - for T lymphocyte immune responses, 174-177
  - from tumor cells, 173-174
- Varian 600 SR machine, 708
- Varicella-zoster virus, 135
- Vascular endothelial growth factor, 207-208
- Vascular marker, soft tissue sarcoma and, 517-518
- Vasculitis, 348, 366-368, 376
- clinical classification of, 367
- Vasculitis (Continued)
- malignancies associated with, 367
  - neoplasm-associated cutaneous leukocytoclastic, 345
  - with septal panniculitis, 348, 356
  - without septal panniculitis, 348-349
- Verrucarin, 162
- Vesiculobullous disorders, 349, 356-357
- Vimentin, soft tissue sarcoma and, 516
- Vinblastine, 157
- Vincristine, 157
- in acute lymphoblastic leukemia, 70-72, 70-73
  - in combination chemotherapy, for advanced sarcoma, 576
  - in osteosarcoma therapy, 561-563
- Vincristine, methotrexate, asparaginase, dexamethasone regimen, 74
- Vindesine, as second-line NSCLC therapy, 460
- Vinorelbine, 157
- in advanced NSCLC, 442
  - in NSCLC, 448-449
  - in SCLC, 469, 471
  - as second-line NSCLC therapy, 459
- Viral infection, following acute leukemia therapy, 135-136
- Vitamin A, 402
- dietary intake of, 404
- Vitamin D, 247, 249
- Vitamin E, 247, 249, 405
- Vitaxin, 209
- Voltage-gated calcium channel, 319
- von Hippel-Lindau syndrome, 207-208
- VP-16, as second-line NSCLC therapy, 460
- Water, chemical shift of, measurement of, 619
- Weight loss
- in cancer, 280
  - see also Cachexia syndrome, 280
- Werner's syndrome, 366
- soft tissue sarcoma associated with, 509
- Western blot analysis, of antineuronal antibodies, 325
- White cell count, in acute lymphocytic leukemia, 83
- World Wide Web, for radiation oncology, 667-668
- Xeroderma Pigmentosum, DNA damage repair and, 107-109
- Yeast artificial chromosome, 34
- Zinostatin, 157
- Zorubicin, in acute lymphoblastic leukemia, 70-72